The Cost of Complacency: A Harm Reduction Funding Crisis
Harm Reduction International releases its annual report exploring the state of harm reduction funding in low- and middle-income countries. More
Several Ministries of Health have written to Danaher requesting that the price of the tests for XDR-TB, HIV and hepatitis — currently priced at $14.90 per test cartridge — also be lowered to no more than $7.97. More
Unitaid’s funding to support the integration of hepatitis C testing and treatment in harm reduction services, while trialing the use of two underused products to prevent infection. More
For a drug policy that makes Europe safer, healthier, and more just! A Manifesto, initiated by C-EHRN, lays down a vision for a pragmatic, innovative, and human rights-centred European drug policy. More
WHO releases a report jointly presenting diagnostic test forecasts across disease areas in recognition of the benefits of addressing HIV and viral hepatitis B and C in a coordinated manner. More
New WHO report flags major increase in sexually transmitted infections, amidst challenges in HIV and hepatitis. More